University of Colorado
Anschutz Medical Campus

Institutional Biosafety Committee (IBC)
Zoom Meeting Minutes
28 September 2026
9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:

[redacted] (JA)
Dr. [redacted] (PD)**
Dr. [redacted] (MF)
Dr. [redacted] (LH)
Dr. [redacted] (BH)
[redacted] (EK)
Dr. [redacted] (SK)
Dr. [redacted] (JL)
Dr. [redacted] (CM)
Dr. [redacted] (Co-chair) (BM)
Dr. [redacted] (Co-chair) (TM)
[redacted] (JR)
Dr. [redacted] (MV)
[redacted] (ZW)

Non-voting IBC Members/Guests:

[redacted] (AA)
[redacted] (QB)
[redacted] (JH)*
[redacted] (JW)
[redacted] (CW)*

I. **Call to Order:** 9:00am (Mountain Time)

II. **Conflict of Interest:**
- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

III. **Review and Approval of Previous Minutes:** 24 August 2026
The minutes were reviewed and approved by the IBC.
Approved = 14
Opposed = 0
Abstained = 0

IV. **IBC Administrative Business:**
1. **IBC Administrative Changes:**
   a. JR's departure from the IBC was announced. Special thanks provided to JR for serving on the IBC.
2. **Protocol Closures:**
   a. [redacted] - # 1197
3. **Protocol Transfers:** None

Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:
During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences,

the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

V. New Business:

1. **Environmental Health and Safety Office Updates:** None
2. **Biosafety Office Updates:**
    a. BH briefed the IBC on the recent CDC-NAC visit for PV containment facility readiness. BH to update the IBC once findings are available.

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Sherbenou, Daniel - # 23-0376: *A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/ Refractory Multiple Myeloma (CaMMouflage Trial)*
2. Abbott, Kaleb - # 26-0186: *A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects with Stage 2 or 3 Neurotrophic Keratitis*
3. Kim, Sunnie - # 23-1329: *A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma*
4. Fabrizio, Vanessa - # 18-2424: *Phase I/II Dose Escalation and Preliminary Efficacy of CD19 Directed CAR-T Cells Generated Using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) in Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL)*

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

1. **Patel, Sapna - # 26-1478: A Phase 1/2 Open-Label Stud to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors**
   Biosafety level(s): BSL-2
   NIH Section(s): III-C
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with no further committee concerns.

2. **Thomas, Janet - # 26-1644: A MASTER PROTOCOL FOR A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BEAM-304 DRUG PRODUCTS IN PATIENTS WITH PHENYLKETONURIA (PKU) HAVING SPECIFIC HOMOZYGOUS OR COMPOUND HETEROZYGOUS MUTATIONS**
   Biosafety level(s): BSL-1
   NIH Section(s): III-C
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with no further committee concerns.

*JH and CW left the meeting at 9:19am.

VIII. New Laboratory Protocol Reviews: None

IX. De Novo Laboratory Protocol Reviews:

1. [redacted] **- # 1426: Varicella Zoster Virus and Herpes Simplex Virus Type 1 Contribution to multisystem diseases**
   Biosafety level(s): BSL-2, BSL-3, ABSL-2
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was deferred by the IBC. The IBC to review the protocol at a later IBC meeting with recommendations to address items including clarifying agent/biomaterial receipt details, updating listed IACUC protocol expiration date(s), adding details to the research narrative, clarifying select agent use and agents administered to animals, updating engineering control details, adding agent signs and symptoms details, and correcting inconsistencies throughout the IBC protocol form.

2. [redacted] **- # 1264: Investigations of bacterial species of interest and the further characterization of their genomes.**
   Biosafety level(s): BSL-2, ABSL-2
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address adding bioagent details, updating the research narrative and agents list, selecting appropriate IBC protocol checkboxes, clarifying laboratory cleaning protocols and animal use, removing outdated details, and correcting inconsistencies through the IBC protocol form.

3. [redacted] **- # 1521: Characterization of antiviral activities of novel HIV-1 inhibitors and virus-host cell interactions**
   Biosafety level(s): BSL-1, BSL-2, BSL-3
   NIH Section(s): III-D-1, III-D-2, III-D-3, III-E-1, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address selecting appropriate IBC protocol checkboxes, clarifying procedures throughout the IBC protocol form, and correcting inconsistencies between the research narrative and other sections of the IBC protocol form.

**PD left the meeting at 09:47am.

4. [redacted] **- # 1526: Structure and function of the spliceosome and the Six1/Eya transcriptional complex**
   Biosafety level(s): BSL-1, BSL-2
   NIH Section(s): III-D-1, III-D-2, III-E-1, III-F
   Approved = 13
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying cell use in the research narrative, updating laboratory cleaning protocols, clarifying “large amount” language, and updating IBC protocol

checkboxes.

5. [redacted] **- # 1177: Interferon signaling in Down syndrome and Development of p53-based cancer therapeutics**
   Biosafety level(s): BSL-2, ABSL-1
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-F
   Approved = 13
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address adding details for rDNA administration, selecting appropriate IBC protocol checkboxes, and adding agent signs and symptoms details.

6. [redacted] **- # 1434: Endocrine response and resistance in breast cancer**
   Biosafety level(s): BSL-2, ABSL-1
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
   Approved = 13
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address clarifying research narrative details, selecting appropriate IBC protocol checkboxes, and clarifying laboratory cleaning protocols.

7. [redacted] **- # 1117: Hormones and breast cancer**
   Biosafety level(s): BSL-1, BSL-2, ABSL-1
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
   Approved = 13
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying procedure details, updating BSLs and IACUC protocol expiration date(s), and selecting appropriate IBC protocol checkboxes.

8. [redacted] **- # 1265: Define and target the mechanisms sustaining the persistently activated phenotypes of pulmonary vascular cells from pulmonary hypertension (PH) patients or PH animal models (cow)**
   Biosafety level(s): BSL-2
   NIH Section(s): III-D-1, III-D-2, III-F
   Approved = 13
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying language for cell types and selecting appropriate IBC protocol checkboxes.

X. Significant Amendment Reviews for Laboratory Protocols:

1. [redacted] **- # 1033: Pulmonary Hypertension: Modeling Heart and Lung Dysfunction**
   Biosafety level(s): BSL-2, ABSL-2
   NIH Section(s): III-D-4
   Approved = 13

Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address clarifying agent administration details, updating BSLs, adding signs and symptoms details, and updating import permit details where appropriate.

2. [redacted] **- # 1711: Understanding platelet development and function in both disease and transfusion**
Biosafety level(s): BSL-1, BSL-2, ABSL-1, ABSL-2
NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including selecting appropriate IBC protocol checkboxes.

3. [redacted] **- # 1707: Neurodevelopmental mechanisms and Rare Diseases** (Previously deferred by the IBC)
Biosafety level(s): BSL-2
NIH Section(s): III-E-1
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address adding agent details throughout IBC protocol form and selecting appropriate IBC protocol checkboxes.

4. [redacted] **- # 1677: Unconventional T cells in tumor immunity.**
Biosafety level(s): BSL-1, BSL-2, ABSL-1
NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including providing location details, updating procedure details, selecting appropriate PPE checkboxes, and updating IACUC protocol expiration date(s).

XI. Exempt Protocols – New/Renewal:

1. [redacted] - # 1782: *Mechanical testing of human and animal cadaver bones, joints, ligaments, and tendons.*
2. [redacted] - # 1489: *Metabolic pathways of obesity and asthma.*
3. [redacted] - # 1509: *Atherosclerosis and Angiogenesis Research*
4. [redacted] - # 1454: *Identification and characterization of variation underlying genetic disorders*
5. [redacted] - # 1547: *Studies of basic molecular and cell biology using the model eukaryote, Saccharomyces cerevisiae (baker's yeast), with a focus on the structure and function of the septin family of proteins, post-transcriptional regulation of gene expression, and the function of genes linked to Parkinson's disease in the turnover of excess or damaged cellular components.*

XII. Exempt Protocol Amendments:

1. [redacted] - # 1583: *Brain injury across the lifespan*
2. [redacted] - # 1105: *Study of autoimmune and acute inflammation*
3. [redacted] - # 1662: *Models for understanding human craniofacial disease and treatments*
4. [redacted] - # 1675: *Therapeutic Targets in Eye Diseases*
5. [redacted] - # 1634: *Immune interactions with commensal fungi in the gut*
6. [redacted] - # 1422: *Molecular mechanisms of protein-membrane interactions*
7. [redacted] - # 1022: *Determining how contexts from aging to exposures alters somatic cell evolutionary trajectories and disease*

XIII. **Additional Business:** None

XIV. **Next Meeting Scheduled:** 26 October 2026, 9:00am (Mountain Time)

XV. **Adjournment:** 10:32am (Mountain Time)